Advertisement


Bridgett Harr, CNP, on Reducing ER Visits and Admissions in High-Risk Head and Neck Cancer Patients

2015 ASTRO Annual Meeting

Advertisement

Bridgett Harr, CNP, of Cleveland Clinic, discusses the advanced practice nurse follow-up clinic, which focuses on symptom management in the first 90 days postchemoradiation (Abstract 3169).



Related Videos

Pancreatic Cancer
Hepatobiliary Cancer

Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers

Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).

CNS Cancers
Gastroesophageal Cancer

Anita Mahajan, MD, on Radiotherapy Advances in the CNS and Aerodigestive Tract

Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).

Lung Cancer

Stephen G. Chun, MD, on NSCLC: Results From NRG Oncology/RTOG 0617

Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).

Symptom Management
Palliative Care
Pain Management

Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).

Advertisement

Advertisement




Advertisement